Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, and seed investors M Ventures, and Arkin Bio Ventures II, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is committed to advancing a differentiated pipeline addressing critical unmet needs in oncology.

Actithera

Steven Kelly

This department manages interactions and communications with the organization's Board of Directors.

Board Relations

This department focuses on overseeing and managing clinical research operations and development processes for medical innovations.

Clinical Development

This department manages governance and strategic oversight for the organization.

Board Affairs

This department is responsible for the overall strategic direction and management of the organization.

Executive Leadership

This department focuses on research and development in oncology and preclinical imaging technologies.

Oncology and Imaging

This department focuses on conducting research and development in pharmacology, particularly in vitro studies.

Actithera

Org chart

Teams

Board Relations

Clinical Development

Board Affairs

Executive Leadership

Oncology and Imaging

Pharmacology Division

Offices

Actithera

Org chart

Teams

Board Relations

Clinical Development

Board Affairs

Executive Leadership

Oncology and Imaging

Pharmacology Division

Offices

Related companies